Israel Englander Aridis Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.0 - $3.65 $149,118 - $272,140	-74,559 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.55 - $7.49 $264,684 - $558,446	74,559 New	74,559 $274,000
Q4 2020 Feb 16, 2021	SELL	$6.07 - $8.01 $68,767 - $90,745	-11,329 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$6.33 - $7.75 $784 - $961	124 Added 1.11%	11,329 $80,000
Q2 2020 Aug 14, 2020	BUY	$5.24 - $8.97 $4,202 - $7,193	802 Added 7.71%	11,205 $74,000
Q1 2020 May 14, 2020	SELL	$4.34 - $8.3 $4,526 - $8,656	-1,043 Reduced 9.11%	10,403 $60,000
Q4 2019 Feb 14, 2020	SELL	$4.16 - $7.1 $58,751 - $100,273	-14,123 Reduced 55.23%	11,446 $51,000
Q3 2019 Nov 14, 2019	BUY	$6.57 - $12.2 $167,988 - $311,941	25,569 New	25,569 $171,000
Q2 2019 Aug 14, 2019	SELL	$7.1 - $11.34 $76,417 - $122,052	-10,763 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$8.15 - $11.59 $10,994 - $15,634	-1,349 Reduced 11.14%	10,763 $118,000
Q4 2018 Feb 14, 2019	SELL	$7.82 - $13.03 $89,718 - $149,493	-11,473 Reduced 48.65%	12,112 $134,000
Q3 2018 Nov 14, 2018	BUY	$11.92 - $13.69 $281,133 - $322,878	23,585 New	23,585 $306,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.